Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Vergote I, Cibula D, Powell M, Laenen A, Nieuwenhuysen EV, Topuz S, González-Martín A, Fujiwara K, Safina S, Bagaméri A, Oliver M, Lee JY, Salutari V, Korach J, Lu CH, Mądry R, Vulsteke C, Colombo N, Sehouli J, Klat J, Ruiz EY, Gilbert L, Pautier P, Pardo B, Kridelka F, Wei J, Toker S, Yamada K, Coleman RL, ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators

Open source

DOI: 10.1016/s1470-2045(26)00223-8
Published: 2026 Sep 7
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00223-8,
  title = {Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.},
  author = {Vergote I and Cibula D and Powell M and Laenen A and Nieuwenhuysen EV and Topuz S and González-Martín A and Fujiwara K and Safina S and Bagaméri A and Oliver M and Lee JY and Salutari V and Korach J and Lu CH and Mądry R and Vulsteke C and Colombo N and Sehouli J and Klat J and Ruiz EY and Gilbert L and Pautier P and Pardo B and Kridelka F and Wei J and Toker S and Yamada K and Coleman RL and ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00223-8},
  url = {https://doi.org/10.1016/s1470-2045(26)00223-8}
}

RIS

TY  - JOUR
TI  - Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.
AU  - Vergote I
AU  - Cibula D
AU  - Powell M
AU  - Laenen A
AU  - Nieuwenhuysen EV
AU  - Topuz S
AU  - González-Martín A
AU  - Fujiwara K
AU  - Safina S
AU  - Bagaméri A
AU  - Oliver M
AU  - Lee JY
AU  - Salutari V
AU  - Korach J
AU  - Lu CH
AU  - Mądry R
AU  - Vulsteke C
AU  - Colombo N
AU  - Sehouli J
AU  - Klat J
AU  - Ruiz EY
AU  - Gilbert L
AU  - Pautier P
AU  - Pardo B
AU  - Kridelka F
AU  - Wei J
AU  - Toker S
AU  - Yamada K
AU  - Coleman RL
AU  - ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00223-8
UR  - https://doi.org/10.1016/s1470-2045(26)00223-8
ER  -

APA

I, V., D, C., M, P., A, L., EV, N., S, T., A, G., K, F., S, S., A, B., M, O., JY, L., V, S., J, K., CH, L., R, M., C, V., N, C., J, S., J, K., EY, R., L, G., P, P., B, P., F, K., J, W., S, T., K, Y., RL, C., & investigators, E. (2026). Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00223-8

Source records

pubmed · retrieved 2026-09-26T06:04:33.995Z